NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Evaluating the Safety and Immune Response to Two Doses of a Dengue Virus Vaccine Administered 12 Months Apart

Phase 1

Completed

Conditions: Dengue

Interventions: Biological: TV003 Vaccine
Biological: Placebo Vaccine

First Posted Date: 2013-02-01

Last Posted Date: 2017-06-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 48

Registration Number: NCT01782300

Locations: 🇺🇸
Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States
🇺🇸
University of Vermont Vaccine Testing Center, Burlington, Vermont, United States

Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 Infection

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Raltegravir

First Posted Date: 2013-01-31

Last Posted Date: 2021-11-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 52

Registration Number: NCT01780831

Locations: 🇿🇦
Umlazi CRS, Durban, KwaZulu-Natal, South Africa
🇹🇭
Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand
🇺🇸
Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States

and more 12 locations

Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart Transplantation

Phase 2

Terminated

Conditions: Primary Heart Transplant
Heart Transplantation
Heart Transplant

Interventions: Drug: bortezomib
Procedure: plasmapheresis

First Posted Date: 2013-01-16

Last Posted Date: 2015-11-11

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 2

Registration Number: NCT01769443

Locations: 🇺🇸
University of Utah, Salt Lake City, Utah, United States
🇺🇸
University of California at San Francisco, San Francisco, California, United States
🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States

and more 11 locations

Safety, Tolerance and Pharmacokinetics of Raltegravir-Containing Antiretroviral Therapy in Infants, Children Infected With HIV and TB

Phase 1

Completed

Conditions: Tuberculosis
HIV Infections

Interventions: Drug: Raltegravir

First Posted Date: 2012-12-18

Last Posted Date: 2021-11-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 40

Registration Number: NCT01751568

Locations: 🇿🇦
Soweto IMPAACT CRS, Johannesburg, Gauteng, South Africa
🇿🇦
Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa
🇿🇦
Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa

and more 1 locations

LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine

Phase 1

Completed

Conditions: Leishmaniasis

Interventions: Biological: GLA-SE
Drug: SE
Biological: LEISH-F3
Biological: MPL-SE

First Posted Date: 2012-12-17

Last Posted Date: 2017-01-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 48

Registration Number: NCT01751048

Locations: 🇺🇸
University of Iowa - Vaccine Research and Education Unit, Iowa City, Iowa, United States

Testing the AVI-7100 Flu Drug in Healthy Volunteers

Phase 1

Completed

Conditions: Influenza

First Posted Date: 2012-12-11

Last Posted Date: 2017-12-26

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 66

Registration Number: NCT01747148

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Adult and Elderly Populations

Phase 2

Completed

Conditions: Influenza

Interventions: Biological: Influenza A/H3N2 variant Vaccine

First Posted Date: 2012-12-10

Last Posted Date: 2014-02-28

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 211

Registration Number: NCT01746082

Locations: 🇺🇸
University of Iowa - Infectious Disease Clinic, Iowa City, Iowa, United States
🇺🇸
Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States
🇺🇸
Group Health Research Institute - Seattle, Seattle, Washington, United States

and more 1 locations

RELIVE Informed Consent Study

Completed

Conditions: Living Donors
Tissue Donors

Interventions: Procedure: Organ Donation

First Posted Date: 2012-12-05

Last Posted Date: 2017-03-27

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 624

Registration Number: NCT01742234

Artemisinin-resistant Malaria in Cambodia

Completed

Conditions: Plasmodium Falciparum Malaria

First Posted Date: 2012-11-29

Last Posted Date: 2018-06-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 561

Registration Number: NCT01736319

Locations: 🇰🇭
National Center for Parasitology, Entomology, and Malaria Controk, Ministry of H, Phnom Penh, Cambodia

Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study

Not Applicable

Completed

Conditions: Dermatitis, Atopic

Interventions: Biological: Fluzone® (Intramuscular) vaccine
Biological: Fluzone® Intradermal Vaccine

First Posted Date: 2012-11-29

Last Posted Date: 2017-03-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 368

Registration Number: NCT01737710

Locations: 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇺🇸
National Jewish Health, Denver, Colorado, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy